Amazon gets $250,000 with additional $350,000 to come for phase 2 HIV trials with AMZ0026

By E. Janene Geiss

Philadelphia, May 31 - Amazon Biotech, Inc. said Wednesday that the company received $250,000 in funding for its phase 2 HIV clinical trials as well as an additional $350,000 in commitments for further funding.

The company said it will use the funding to begin the trials once the Food and Drug Administration approves the protocol, according to a company news release.

The company said it has submitted to the FDA its protocol to test AMZ0026 as an antiviral and immuno-modulating agent in non-treated HIV subjects. The study design includes non-symptomatic HIV subjects who are not yet treated with Highly Active Anti-Retroviral Therapy, with 50% of the subjects receiving a placebo and 50% receiving AMZ0026.

The six-month study will include the monitoring of T-cell increases and HIV plasma viral load decreases, officials said.

Amazon is a New York City natural plant pharmaceutical drug company, primarily developing immunomodulator drugs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.